"Glatiramer Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068717
|
| MeSH Number(s) |
D12.644.219
|
| Concept/Terms |
TV 5010- TV 5010
- 5010, TV
- TV5010
- TV-5010
|
Below are MeSH descriptors whose meaning is more general than "Glatiramer Acetate".
Below are MeSH descriptors whose meaning is more specific than "Glatiramer Acetate".
This graph shows the total number of publications written about "Glatiramer Acetate" by people in this website by year, and whether "Glatiramer Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glatiramer Acetate" by people in Profiles.
-
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
-
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021. Mult Scler. 2025 Nov; 31(13):1595-1599.
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
-
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
-
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013 Dec; 113(4):415-20.
-
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1829-39.
-
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
-
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
-
Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity. 2008 Aug; 41(5):363-71.
-
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.